Table 2.
SNP | BP | Minor Allele | MAF in Cases | MAF in Control Subjects | Major Allele | CHISQ | OR (95% CI) | p |
---|---|---|---|---|---|---|---|---|
Females (279 cases, 573 control subjects) | ||||||||
rs7202127 | 48,882,871 | C | .244 | .243 | G | .003 | 1.006 (.795–1.274) | .9588 |
rs1540624 | 48,885,507 | G | .401 | .445 | A | 2.908 | .8364 (.681–1.027) | .0881 |
rs2302717 | 48,886,027 | T | .149 | .198 | C | 6.137 | .7074 (.538–.931) | .0132ab |
rs7191958 | 48,889,674 | A | .267 | .316 | G | 4.266 | .789 (.630–.988) | .0389a |
rs2302679 | 48,903,279 | T | .362 | .374 | C | .245 | .9483 (.769–1.17) | .6206 |
rs1872691 | 48,907,711 | A | .195 | .170 | G | 1.624 | 1.184 (.913–1.535) | .2026 |
rs1064448 | 48,908,384 | T | .475 | .464 | G | .172 | 1.044 (.852–1.278) | .6782 |
Males (1090 cases, 636 control subjects) | ||||||||
rs7202127 | 48,882,871 | C | .243 | .256 | G | .661 | .936 (.798–1.098) | .4162 |
rs1540624 | 48,885,507 | G | .430 | .443 | A | .497 | .9511 (.827–1.093) | .4807 |
rs2302717 | 48,886,027 | T | .184 | .179 | C | .137 | 1.034 (.864–1.238) | .7117 |
rs7191958 | 48,889,674 | A | .301 | .314 | G | .662 | .9398 (.809–1.092) | .4159 |
rs2302679 | 48,903,279 | T | .374 | .351 | C | 1.815 | 1.104 (.956–1.275) | .1779 |
rs1872691 | 48,907,711 | A | .183 | .174 | G | .425 | 1.062 (.886–1.273) | .5143 |
rs1064448 | 48,908,384 | T | .485 | .462 | G | 1.712 | 1.097 (.955–1.26) | .1907 |
BP, base pair; CHISQ, Chi-squared test; CI, confidence interval; MAF, minor allele frequency; OR, estimated odds ratio; SNP, single nucleotide polymorphisms.
Associations attaining nominal significance (p ≤ .05).
Those remaining significant after 10,000 permutations.